These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7416212)

  • 1. The use of medroxyprogesterone acetate for relief of climacteric symptoms.
    Morrison JC; Martin DC; Blair RA; Anderson GD; Kincheloe BW; Bates GW; Hendrix JW; Rivlin ME; Forman EK; Propst MG; Needham R
    Am J Obstet Gynecol; 1980 Sep; 138(1):99-104. PubMed ID: 7416212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case for concern?
    Gartland A
    Nurs Times; 1983 May 4-10; 79(18):10-1. PubMed ID: 6222288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of medroxyprogesterone acetate to prevent menopausal symptoms.
    Bullock JL; Massey FM; Gambrell RD
    Obstet Gynecol; 1975 Aug; 46(2):165-8. PubMed ID: 1153148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of breast cancer with medroxyprogesterone acetate.
    Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
    Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depo-Provera--ethical issues in its testing and distribution.
    Potts M; Paxman JM
    J Med Ethics; 1984 Mar; 10(1):9-20. PubMed ID: 6231379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depo Provera: still controversial.
    Wren LM
    Int Health News; 1988 Feb; 9(2):2-3, 8. PubMed ID: 12179873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged gynecologic and endocrine manifestations subsequent to administration of medroxyprogesterone acetate during pregnancy.
    Turner SJ; Mizock GB; Feldman GL
    Am J Obstet Gynecol; 1966 May; 95(2):222-7. PubMed ID: 5935707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception.
    Cromer BA; Smith RD; Blair JM; Dwyer J; Brown RT
    Pediatrics; 1994 Nov; 94(5):687-94. PubMed ID: 7936897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes.
    Albrecht BH; Schiff I; Tulchinsky D; Ryan KJ
    Am J Obstet Gynecol; 1981 Mar; 139(6):631-5. PubMed ID: 7211966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of Depo-Provera in East London.
    Savage W
    Fertil Contracept; 1978 Jul; 2(3):41-7. PubMed ID: 12260723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
    Pardthaisong T; Gray RH; McDaniel EB
    Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depo-Provera: just another contraceptive?
    Jones M
    Fertil Contracept; 1978 Apr; 2(2):26-9. PubMed ID: 12336094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medroxyprogesterone acetate and homozygous sickle-cell disease.
    De Ceulaer K; Gruber C; Hayes R; Serjeant GR
    Lancet; 1982 Jul; 2(8292):229-31. PubMed ID: 6178915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
    Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
    Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ask the experts: progestin-only contraceptives.
    Hatcher RA; Schnare S
    Contracept Technol Update; 1993 Jul; 14(7):114-5. PubMed ID: 12286999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of Depo-Provera on carbohydrate and lipid metabolism.
    Liew DF; Ng CS; Yong YM; Ratnam SS
    Contraception; 1985 Jan; 31(1):51-64. PubMed ID: 3157546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an injectable progestin-estrogen as a contraceptive.
    Scommegna A; Lee AW; Borushek S
    Am J Obstet Gynecol; 1970 Aug; 107(8):1147-55. PubMed ID: 4917852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Contraception with injectable long-acting preparation depo-provera].
    Prilepskaia VN; Kondrikov NI; Tagieva TT
    Akush Ginekol (Mosk); 1995; (3):7-10. PubMed ID: 7653732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oral medroxyprogesterone acetate on menopausal symptoms in patients with endometrial carcinoma.
    Aslaksen K; Frankendal B
    Acta Obstet Gynecol Scand; 1982; 61(5):423-8. PubMed ID: 6760653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.